Expertise in
1
conditions

Michel Pavic

Sherbrooke, QC, CA 
Expertise in
1
conditions
Sherbrooke, QC, CA 

Overview

Michel Pavic practices practicing medicine in Sherbrooke, Canada.

Mr. Pavic is highly rated in 1 condition, according to our data. His clinical expertise encompasses Acute Nephritic Syndrome, Multiple Myeloma, Sarcoidosis, and Secondary Immunodeficiency (SID).

He is actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Sherbrooke, QC, Canada
Other Locations
Sherbrooke, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Other
Study Phase: Not Applicable
Modulation of Immune Response and Side Effects of Cancer Treatments by Aerobic Exercise: Role of Exercise Intensity
Modulation of Immune Response and Side Effects of Cancer Treatments by Aerobic Exercise: Role of Exercise Intensity
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

69 Total Publications

The Acute Response of Cytotoxic T Cells Following Work-Matched Continuous Moderate Intensity and High Intensity Interval Exercise in Metastatic Cancer Patients Undergoing Chemotherapy : a Pilot Study.
The Acute Response of Cytotoxic T Cells Following Work-Matched Continuous Moderate Intensity and High Intensity Interval Exercise in Metastatic Cancer Patients Undergoing Chemotherapy : a Pilot Study.
Journal: Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme
Published: August 26, 2026

Frequently Asked Questions about Michel Pavic

Is Michel Pavic a top-rated expert for Acute Nephritic Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Michel Pavic is classified as an Advanced expert for Acute Nephritic Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michel Pavic participate in research or clinical trials?

Yes. Michel Pavic has published 69 articles and abstracts on conditions like Acute Nephritic Syndrome. You can view a list of Michel Pavic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pavic's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile